Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a ...

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its ...

The world-class, low-cost gene editing solution named "BIRSA 101", in honour of Bhagwan Birsa Munda, remembered as a great ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect ...

Agios reported mixed results from a Phase 3 study of its drug Pyrukynd in sickle cell, raising doubts about the drug's ...

The CRISPR Cas9 gene editing tool — the genetic scissors that won the 2020 Nobel Prize in Chemistry — is essentially based on ...

India has launched BIRSA 101, the nation’s first indigenous CRISPR-based gene therapy for Sickle Cell Disease, marking a ...

Shares in Agios Pharma lost nearly half their value in pre-market trading today after it posted mixed clinical results from a ...

Shares of Agios Pharmaceuticals sank after the company said a phase three trial of its mitapivat drug to treat Sickle Cell Disease missed some of its endpoints. The stock fell 34% to $30 after closing ...

PRNewswire/ - Medunik USA, a specialty pharmaceutical company, and part of Duchesnay Pharmaceutical Group (DPG), is dedicated to providing patients with rare diseases access to orphan drugs. Medunik ...

Launching the therapy, Dr. Jitendra Singh declared that India has officially begun its decisive march toward a Sickle ...